Clinical trial
A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
NCT06139406 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
- Lead sponsor
- Janssen Research & Development, LLC
- Phase
- Phase 1
- Overall status
- Active, not recruiting
- Start date
- December 6, 2023
- Completion date
- September 30, 2026
- Enrollment
- 70 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.